Navigation Links
Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)
Date:5/20/2013

ent of drug-resistant epilepsy (DRE), major depressive disorder (MDD), and treatment-resistant depression.

The Monarch consists of a small stimulator that can be placed in a pocket or worn at the waist, and an electric patch that is placed on the forehead. The patch stimulates the trigeminal nerve through the surface of the skin, and is used primarily while the patient is asleep.

NeuroSigma is the exclusive worldwide licensee of UCLA's entire TNS intellectual property portfolio and continues to develop additional technologies and target additional indications.

CAUTION: In the United States, both eTNS™ and sTNS™ are investigational devices and are limited by Federal (or United States) law to investigational use.

eTNS, sTNS, Monarch, and the Monarch eTNS are trademarks of NeuroSigma, Inc.

About NeuroSigma, Inc.
NeuroSigma is a Los Angeles-based medical device company established to develop early stage technologies with the potential to transform medical practice and patients' lives.  Currently, NeuroSigma is focused on neuromodulation therapies and has amassed significant intellectual property licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including TNS therapies for epilepsy, depression, post-traumatic stress disorder (PTSD) and attention-deficit hyperactivity disorder (ADHD). For more information about NeuroSigma, please visit www.neurosigma.com.

Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements, including but not limited to, research and development outcomes, efficacy, adverse reactions, market and product potential, product availability and other statements regarding our eTNS™ and sTNS™ systems.  These statements are based on current
'/>"/>

SOURCE NeuroSigma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Positive Clinical Study Results for BSPs HyperQ Technology
3. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
4. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
5. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
6. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
7. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
8. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
9. Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
10. Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association
11. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015 /PRNewswire/ ... next-generation antibiotics, today announced positive top-line results from ... lead drug candidate MRX-I. MRX-I is an oral ... as MRSA and VRE, while offering physicians and ... than currently available oxazolidinone agents. ...
(Date:8/31/2015)... ... August 31, 2015 , ... The ... successful food and beverage processors, equipment manufacturers and leaders in the field of ... industrial weighing and formulation for manufacturers of bakery and snacks; beverages; dairy; meat, ...
(Date:8/28/2015)... -- According to a new market research ... Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem Cells, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 2,150.48 Million in 2015, ... 2020. Browse 74 Tables and 95 ...
(Date:8/28/2015)... NY (PRWEB) , ... August 28, 2015 , ... Since the initial launch of FireflySci ... their quirky humor and excellent customer service. Images such as the Fonz in a ... to add some flavor to the humdrum spectroscopy field. , FireflySci is proud ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2
... Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today ... an additional 180 days to regain compliance with NASDAQ,s $1.00 ... on May 3, 2010, CTI was notified by NASDAQ that ... for continued listing and was provided until November 1, 2010 ...
... Nov. 2, 2010 Cadence Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA) has granted marketing approval for ... formulation of acetaminophen to be approved in the United ... to moderate pain, the management of moderate to severe ...
... 2, 2010 Modern Plastics offers SUSTARIN® C ... manufactured by ROCHLING Engineering Plastics. The technology ... sheet and rod are free of centerline or core ... stability for close tolerance parts. A low coefficient of ...
Cached Biology Technology:NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule 2Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 2Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 3Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 4Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 5Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 6Modern Plastics SUSTARIN® C (Acetal) Product Uses Special Manufacturing Technology to Ensure Every Sheet and Rod Are Free of Centerline or Core Porosity 2
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
(Date:7/31/2015)... juillet 2015 La 10e Conférence internationale ... organisée par le BGI du 22 au 25 ... en Chine. La conférence célèbre son ... 2006, l,ICG est devenue l,une des réunions annuelles ... « omiques » et c,est aussi la plus dynamique, la ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... the short end of the stick, in this case the ... at the ends of chromosomes, can be thought of as ... neighboring chromosomes. It is typical for telomeres to ... a new study from Brigham and Women,s Hospital (BWH) suggest ...
... to the way scientists name new plants that took effect ... Latin requirement - a stipulation that descriptions or diagnoses of ... rules make it possible to take full advantage of an ... particular species is indeed new to science: Many studies now ...
... 2012Healthy individuals who carry a gene variation linked to ... their brains that may help explain how the gene ... results of this innovative brain imaging study are described ... Brain Connectivity, a bimonthly peer-reviewed publication from Mary ...
Cached Biology News:The long, err, short of it 2
Human Glypican 2 Biotinylated Affinity Purified PAb...
B2-Microgloulin...
... Molecular Imaging's proprietary Focus™ detector technology, while ... the R4. The microPET Focus 120 ... avaiable PET scanner. Focus scanners also ... scinitallor based PETsystems. The combination of ...
...
Biology Products: